Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Breast cancer in systemic lupus erythematosus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. 5-year outcome after complete mesocolic excision for right-sided colon cancer: a population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: The CAPOX regimen is used for adjuvant treatment of colorectal cancer. A well-known side effect of oxaliplatin, which often leads to dose modification (DM), is acute neuropathy (AN). AN is provoked by cold, and it could therefore be expected that the degree of AN and thereby DM is more pronounced in the winter period compared to the summer period.

METHOD: Patients with colorectal cancer who received adjuvant CAPOX from January 2005 to August 2011 were reviewed. Out of 108 patients who received adjuvant CAPOX, the oxaliplatin dose was reduced in 92 (85%) patients due to AN. Seventeen out of 31 (55%) patients already had a DM of oxaliplatin in the second cycle during the winter period (December to February; mean temperature 0.1-1.8°C), while in the summer period (June to August; mean temperature 15.1-16.3°C), only 4 (13%) patients needed DM (OR = 2.5, p = 0.022).

CONCLUSION: In this study, we found that the risk of DM and discontinuation of oxaliplatin is highest in the winter period compared to the other seasons. This study draws attention to the importance of training in the proper handling of the acute neurotoxicity of oxaliplatin.

OriginalsprogEngelsk
TidsskriftOncology
Vol/bind87
Udgave nummer3
Sider (fra-til)167-72
Antal sider6
ISSN0030-2414
DOI
StatusUdgivet - 2014

ID: 44960294